Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMIRA Pharmaceuticals, Inc. Common Stock

MIRA Pharmaceuticals, Inc. Common Stock

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
0.6221 USD 0.00 ( 0.19%)
Last update at 2026-11-11T21:00:00Z
VOLUME
52540
Market Cap
12.57M

Momentum Score

…

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.60
Low
0.63
High
52 Week Price Range
0.63
Low
7.98
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.62
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-634.30%
Net Debt
-4.60M
ROCE
-161.12%
Diluted EPS TTM
-0.66

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Income before tax -7.06M -2.18M -
Net income -7.06M -2.18M -
Selling general administrative 2.99M 0.77M -
Ebit -7.05M -2.15M -0.20M
Ebitda -7.05M -2.15M -
Operating income -7.05M -2.15M -
Other operating expenses 7.05M 2.15M -
Interest expense 0.01M 0.02M -
Net interest income -0.01M -0.02M -
Total revenue 0.00M 0.00M -
Total operating expenses 7.05M 2.15M -
Total other income expense net -0.01M -0.02M -
Net income from continuing ops -7.06M -2.18M -
Net income applicable to common shares -7.06M -2.18M -0.20M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 4.93M 0.86M 3.36M -
Other current assets 0.24M 0.14M 0.10M -
Total liab 0.56M 1.45M 1.09M -
Total stockholder equity 4.37M -0.60M 2.26M -
Other current liab 0.01M 0.03M 0.57M -
Common stock 0.00M 0.01M 0.01M 0.01M
Capital stock - 0.01M 0.01M -
Retained earnings -21.29M -9.30M -2.24M -0.07M
Other assets - - 0.45M 0.02M
Cash 4.60M 0.35M 2.81M -
Total current liabilities 0.56M 1.37M 1.09M 0.09M
Current deferred revenue 0.00M - - -
Net debt -4.60M 0.14M -2.52M -
Short term debt 0.01M 0.41M 0.29M -
Short long term debt - 0.13M 0.29M -
Short long term debt total 0.01M 0.49M 0.29M -
Other stockholder equity 25.66M 8.70M 4.50M -0.01M
Property plant equipment - 0.36M - -
Total current assets 4.86M 0.49M 2.91M 0.00M
Net tangible assets - -0.60M 2.26M -0.07M
Net receivables 0.01M - - -
Accounts payable 0.54M 0.93M 0.23M -
Non currrent assets other 0.07M - - -
Non current assets total 0.07M 0.36M 0.45M -
Capital lease obligations - 0.36M 0.00M -
Breakdown 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31
Change to liabilities 0.15M 0.78M 0.00M
Net borrowings -0.16M 0.20M 0.27M
Total cash from financing activities 3.15M 4.18M 0.21M
Change to operating activities -0.01M -0.01M -0.01M
Net income -7.06M -2.18M -0.20M
Change in cash -2.46M 2.81M 0.01M
Begin period cash flow 2.81M 0.00M -
End period cash flow 0.35M 2.81M 0.00M
Total cash from operating activities -5.60M -1.38M -0.20M
Issuance of capital stock 2.90M 4.50M -
Other cashflows from financing activities 0.24M -0.32M -0.06M
Change to netincome 1.31M 0.02M 0.02M
Capital expenditures 0.00M 0.00M 0.00M
Change in working capital 0.15M 0.78M -
Stock based compensation 1.30M 0.00M -
Other non cash items 0.01M 0.02M -
Free cash flow -5.60M -1.38M -

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
MIRA
MIRA Pharmaceuticals, Inc. Common Stock		 0.00
0.19%		 0.62 - - - 1.93 -1.45
LLY
Eli Lilly and Company		 5.00
0.35%		 1437.29 38.16 24.15 12.72 29.95 25.43
JNJ
Johnson & Johnson		 -0.02
0.01%		 280.76 30.96 20.79 6.58 7.55 19.73
ABBV
AbbVie Inc		 1.09
0.37%		 294.98 74.10 16.21 7.22 50.46 27.04
RHHVF
Roche Holding AG Participation		 -6.12
1.25%		 484.80 24.16 16.53 5.71 8.88 14.76

Profile*

MIRA Pharmaceuticals, Inc. Common Stock

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

1200 Brickell Avenue, Miami, FL, United States, 32183

786-432-9792

https://mirapharmaceuticals.com

Name Title Year Born
Mr. Erez Aminov CEO & Chairman 1979
Ms. Michelle Yanez M.B.A. CFO, Secretary & Treasurer 1973
Dr. Itzchak Angel Ph.D. Chief Scientific Advisor NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…